Health Care & Life Sciences » Biotechnology | Array BioPharma Inc.

Array BioPharma Inc. | Income Statement

Fiscal year is July-June. All values USD Thousands.
2014
2015
2016
2017
2018
Sales/Revenue
42,078.00
51,909.00
137,879.00
150,852.00
173,768.00
Cost of Goods Sold (COGS) incl. D&A
45,965.00
44,392.00
23,166.00
35,395.00
59,374.00
Gross Income
3,887.00
7,517.00
114,713.00
115,457.00
114,394.00
SG&A Expense
68,929.00
85,875.00
196,922.00
217,535.00
244,321.00
EBIT
72,816.00
78,358.00
82,209.00
102,078.00
129,927.00
Unusual Expense
2,802.00
80,010.00
-
4,100.00
8,844.00
Non Operating Income/Expense
-
17,896.00
-
897.00
69.00
Interest Expense
9,716.00
10,247.00
10,874.00
12,333.00
10,814.00
Pretax Income
85,257.00
9,369.00
92,840.00
116,818.00
145,046.00
Income Tax
-
-
-
-
2,300.00
Consolidated Net Income
85,257.00
9,369.00
92,840.00
116,818.00
147,346.00
Net Income
85,257.00
9,369.00
92,840.00
116,818.00
147,346.00
Net Income After Extraordinaries
85,257.00
9,369.00
92,840.00
116,818.00
147,346.00
Net Income Available to Common
85,257.00
9,369.00
92,840.00
116,818.00
147,346.00
EPS (Basic)
0.69
0.07
0.65
0.72
0.74
Basic Shares Outstanding
123,403.00
136,679.00
142,964.00
163,207.00
198,490.00
EPS (Diluted)
0.69
0.07
0.65
0.72
0.74
Diluted Shares Outstanding
123,403.00
141,692.00
142,964.00
163,207.00
198,490.00
EBITDA
68,310.00
74,656.00
80,680.00
100,010.00
127,691.00
Non-Operating Interest Income
77.00
68.00
243.00
796.00
4,470.00

About Array BioPharma

View Profile
Address
3200 Walnut Street
Boulder Colorado 80301
United States
Employees -
Website http://www.arraybiopharma.com
Updated 07/08/2019
Array BioPharma, Inc. engages in the research, development, and commercialization of targeted small molecule drugs for the treatment of cancer and other high-burden diseases. Its portfolio includes Binimetinib, Selumetinib, Encorafenib, Filanesib, Ipatasertib, Varltinib, Danoprevir, ARRY-797, Larotrectinib, Tucatinib, ARRY-382, Motolimod, Prexasertib, GDC-0575, LOXO-292, LOXO-195, and AK-1830. The company was founded by Kevin Koch, Anthony Piscopio, K.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.